Prenggono, Muhammad Darwin
(Oncology Reviews, 2021-10-01)
Imatinib and nilotinib are first-line treatments for chronic myeloid leukemia (CML) patients, which act specifically against target cells. However, these drugs may cause side effects, such as electrolyte disturbances. This ...